CALGARY, ALBERTA--(Marketwire - July 25, 2007) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (“SCT”) is pleased to announce the initiation of a pre-clinical comparator study designed to characterize the neuroregenerative effects of stem cell proliferative agents plus erythropoietin (EPO) in an animal model of traumatic brain injury (TBI). This study represents a promising new program launch that builds upon intellectual property held by SCT and supported by fundamental findings from the laboratory of Dr. Samuel Weiss at the University of Calgary. SCT recently announced encouraging results from the interim analysis of its ongoing Phase IIa clinical study in stroke patients with a regimen of human chorionic gonadotropin (hCG) followed by EPO. The current study will explore a different but related therapeutic area, TBI.
